DK3300729T3 - Terapeutiske sammensætninger indeholdende macitentan - Google Patents

Terapeutiske sammensætninger indeholdende macitentan Download PDF

Info

Publication number
DK3300729T3
DK3300729T3 DK17191033.4T DK17191033T DK3300729T3 DK 3300729 T3 DK3300729 T3 DK 3300729T3 DK 17191033 T DK17191033 T DK 17191033T DK 3300729 T3 DK3300729 T3 DK 3300729T3
Authority
DK
Denmark
Prior art keywords
compositions containing
therapeutic compositions
containing macitentan
macitentan
therapeutic
Prior art date
Application number
DK17191033.4T
Other languages
Danish (da)
English (en)
Inventor
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3300729(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK3300729T3 publication Critical patent/DK3300729T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK17191033.4T 2008-08-13 2009-08-12 Terapeutiske sammensætninger indeholdende macitentan DK3300729T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13
EP09786912.7A EP2315587B1 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Publications (1)

Publication Number Publication Date
DK3300729T3 true DK3300729T3 (da) 2020-01-20

Family

ID=41346591

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17191033.4T DK3300729T3 (da) 2008-08-13 2009-08-12 Terapeutiske sammensætninger indeholdende macitentan
DK09786912.7T DK2315587T3 (en) 2008-08-13 2009-08-12 THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09786912.7T DK2315587T3 (en) 2008-08-13 2009-08-12 THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN

Country Status (30)

Country Link
US (3) US8809334B2 (enExample)
EP (2) EP3300729B1 (enExample)
JP (3) JP5764061B2 (enExample)
KR (1) KR101678699B1 (enExample)
CN (1) CN102099026B (enExample)
AR (1) AR073031A1 (enExample)
AU (1) AU2009280843B2 (enExample)
BR (1) BRPI0917661B8 (enExample)
CA (1) CA2731370C (enExample)
CY (2) CY1119826T1 (enExample)
DK (2) DK3300729T3 (enExample)
ES (2) ES2763176T3 (enExample)
HK (1) HK1253355B (enExample)
HR (2) HRP20171917T1 (enExample)
HU (2) HUE047767T2 (enExample)
IL (1) IL211143A0 (enExample)
LT (2) LT3300729T (enExample)
MA (1) MA32614B1 (enExample)
MX (1) MX350011B (enExample)
MY (1) MY178894A (enExample)
NO (1) NO2315587T3 (enExample)
NZ (1) NZ591601A (enExample)
PL (2) PL3300729T3 (enExample)
PT (2) PT2315587T (enExample)
RU (1) RU2519161C2 (enExample)
SI (2) SI3300729T1 (enExample)
SM (2) SMT201900740T1 (enExample)
TW (1) TWI446911B (enExample)
WO (1) WO2010018549A2 (enExample)
ZA (1) ZA201101900B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006290309B2 (en) 2005-09-12 2012-04-05 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
JP5522030B2 (ja) 2008-02-28 2014-06-18 日本新薬株式会社 線維化抑制剤
NO2315587T3 (enExample) 2008-08-13 2018-03-24
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
JP2020502121A (ja) 2016-12-14 2020-01-23 レスピラ セラピューティクス インコーポレイテッドRespira Therapeutics,Inc. 肺高血圧症および他の肺障害の処置のための方法および組成物
AU2019339401B9 (en) * 2018-09-14 2022-11-03 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
BR112021011999A2 (pt) * 2018-12-21 2021-09-08 Actelion Pharmaceuticals Ltd Composição farmacêutica para o tratamento de hipertensão arterial pulmonar
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
US12485119B2 (en) 2019-11-29 2025-12-02 Actelion Pharmaceuticals Ltd Methods of treating pulmonary arterial hypertension
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
CA3240614A1 (en) 2021-12-31 2023-07-06 Stuart Rich Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539333A (en) * 1976-05-11 1985-09-03 Burroughs Wellcome Co. Prostacyclin, methods of using and method of making
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc 5,6,7−トリノル−4,8−インタ−m−フエニレンPGI↓2誘導体
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
PT1345920E (pt) * 2000-12-18 2006-08-31 Actelion Pharmaceuticals Ltd Novas sulfonamidas e sua utilizacao como antagonistas dos receptores de endotelina
CN1481244A (zh) * 2000-12-19 2004-03-10 Ĭ��ר���ɷ����޹�˾ 含有吡唑并[4,3-d]嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (enExample) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
BR0316724A (pt) * 2002-12-02 2005-10-18 Actelion Pharmaceuticals Ltd Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
AU2006290309B2 (en) * 2005-09-12 2012-04-05 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US8541433B2 (en) * 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
NO2315587T3 (enExample) 2008-08-13 2018-03-24

Also Published As

Publication number Publication date
MY178894A (en) 2020-10-21
SMT201900740T1 (it) 2020-01-14
PL3300729T3 (pl) 2020-04-30
MX350011B (es) 2017-08-22
BRPI0917661A2 (pt) 2015-12-01
JP2015180683A (ja) 2015-10-15
JP2011530581A (ja) 2011-12-22
CN102099026A (zh) 2011-06-15
BRPI0917661B1 (pt) 2019-12-17
EP3300729B1 (en) 2019-10-09
BRPI0917661B8 (pt) 2021-05-25
SI2315587T1 (en) 2018-04-30
US20110136818A1 (en) 2011-06-09
US9173881B2 (en) 2015-11-03
EP3300729A1 (en) 2018-04-04
ES2763176T3 (es) 2020-05-27
US20160022678A1 (en) 2016-01-28
EP2315587B1 (en) 2017-10-25
US20140329824A1 (en) 2014-11-06
PL2315587T3 (pl) 2018-03-30
HRP20192204T1 (hr) 2020-03-06
MA32614B1 (fr) 2011-09-01
HK1253355B (en) 2020-06-19
HUE047767T2 (hu) 2020-05-28
KR20110045006A (ko) 2011-05-03
HRP20171917T1 (hr) 2018-02-09
CY1122641T1 (el) 2021-03-12
JP5956025B2 (ja) 2016-07-20
AU2009280843B2 (en) 2015-03-05
US8809334B2 (en) 2014-08-19
DK2315587T3 (en) 2018-01-02
JP2015187148A (ja) 2015-10-29
WO2010018549A2 (en) 2010-02-18
JP5764061B2 (ja) 2015-08-12
AU2009280843A1 (en) 2010-02-18
AR073031A1 (es) 2010-10-06
NO2315587T3 (enExample) 2018-03-24
HUE036071T2 (hu) 2018-06-28
ZA201101900B (en) 2012-08-29
CY1119826T1 (el) 2018-06-27
EP2315587A2 (en) 2011-05-04
PT3300729T (pt) 2020-01-20
MX2011001625A (es) 2011-03-29
CA2731370A1 (en) 2010-02-18
HK1253355A1 (en) 2019-06-14
TWI446911B (zh) 2014-08-01
IL211143A0 (en) 2011-04-28
US9597331B2 (en) 2017-03-21
KR101678699B1 (ko) 2016-11-23
RU2519161C2 (ru) 2014-06-10
CN102099026B (zh) 2012-08-29
CA2731370C (en) 2017-03-14
LT3300729T (lt) 2020-01-10
RU2011109084A (ru) 2012-09-20
LT2315587T (lt) 2018-01-10
JP5956026B2 (ja) 2016-07-20
TW201010985A (en) 2010-03-16
SMT201700592T1 (it) 2018-03-08
PT2315587T (pt) 2018-01-31
SI3300729T1 (sl) 2020-02-28
WO2010018549A3 (en) 2010-07-29
NZ591601A (en) 2012-12-21
ES2652590T3 (es) 2018-02-05

Similar Documents

Publication Publication Date Title
DK3300729T3 (da) Terapeutiske sammensætninger indeholdende macitentan
PT2448582T (pt) Compostos e composições terapêuticas
DK2634232T3 (da) Sammensætninger
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
DE602008002756D1 (de) Bauzusammensetzung
ES2628203T8 (es) Composiciones antitranspirantes
BRPI0810634A2 (pt) Composições fungicidas
BRPI0914746A2 (pt) composições fungicidas
BRPI0917231A2 (pt) composição
IT1392101B1 (it) Composizione comprendente isoflavoni
FR2933868B1 (fr) Compositions cosmetiques
EP2236149A4 (en) MEDICAL COMPOSITION
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DK2285413T3 (da) Farmaceutisk sammensætning
EP2335669A4 (en) COMPOSITION FOR MEANS FOR DESENSIBILIZING TEETH
BRPI0921313A2 (pt) composição farmaucêutica
EP2357204A4 (en) COMPOSITION
BRPI0912171A2 (pt) composição farmacêutica
EP2249776A4 (en) SHOWER COMPOSITIONS
BRPI0921301A2 (pt) composição farmacêutica
BRPI0917584A2 (pt) composição
BRPI0909764A2 (pt) compostos terapêuticos
BRPI0920692A2 (pt) composição
BRPI0906879A2 (pt) Compostos terapêuticos